MedTrace Logo

Effects of Detraining in Endurance Athletes With Atrial Fibrillation

NCT04991337 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-12-23

No results posted yet for this study

Summary

Atrial fibrillation (AF) affects more than 43 million people worldwide, but specific exercise recommendations do not exist for this group of patients. Despite a lack of evidence, athletes are often advised to reduce exercise intensity (detraining) after being diagnosed with AF. This randomized controlled trial will be the first study that investigates effects of detraining in endurance athletes. Participants will be randomized to an intervention group that will be instructed to refrain from high intensity exercise, and a control group. The study aims to clarify whether detraining might reduce the burden of AF and has the potential to guide development of exercise guidelines for AF patients.

Conditions

Interventions

BEHAVIORAL

Detraining group

Detraining is defined as exercise corresponding to a heart rate ≤75% of maximum heart rate and ≤80% of the self-reported average weekly amount of exercise (hours/week) during the past six months, for a period of 16 weeks.

BEHAVIORAL

Control group

At least three weekly sessions of high intensity exercise, corresponding to a heart rate ≥85% of maximum heart rate, and otherwise continue endurance exercise as usual.

Sponsors & Collaborators

  • St. Olavs Hospital

    collaborator OTHER

  • Baker Heart and Diabetes Institute

    collaborator OTHER

  • Universitaire Ziekenhuizen KU Leuven

    collaborator OTHER

  • University Hospital, Antwerp

    collaborator OTHER

  • AZ Jan Palfijn Gent

    collaborator OTHER

  • Jessa Hospital

    collaborator OTHER

  • Vestre Viken Hospital Trust

    lead OTHER

Principal Investigators

  • Marius Myrstad, |MD, PhD · Vestre Viken Health trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-05
Primary Completion
2024-01-01
Completion
2024-01-01

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04991337 on ClinicalTrials.gov